To systematically evaluate the safety of Lianhuaqingwen preparations in clinical practice.Methods:We searched the Chinese Biomedical Literature Database(CBM)，the Chinese Journal Full-text Database(CJFD)，MEDLINE，Embase，to collect clinical literature about the randomized controlled clinical trials(RCT) of Lianhuaqingwen Capsules and Lianhuaqingwen Granules，the search time limit was set from January 2005 to July 2020.Results:The research found 128 RCTs，8411 cases in Lianhuaqingwen preparation group and 8031 cases in control group.349 cases(4.1%) in the Lianhuaqingwen preparation group，versus 443 cases(5.5%) in control group showed adverse reactions.The relative risk of adverse reaction rate between the Lianhuaqingwen preparation group and the control group was [RR=0.76，95%CI(0.68 to 0.86)，P<0.05].This showed that the adverse incidence of Lianhuaqingwen preparation is lower than that of the control group.Subgroup analysis of Lianhuaqingwen preparations alone [RR=0.73，95%CI(0.59 to 0.91)，P<0.05]，combined use of Lianhuaqingwen preparations [RR=0.77，95%CI(0.66 to 0.91)，P<0.05]，Lianhuaqingwen Capsules [RR=0.81，95%CI(0.49 to 0.82),P<0.05]，Lianhuaqingwen Granules [RR=0.63，95%CI(0.49 to 0.82)，P<0.05].It was suggested that the incidence of adverse reactions of Lianhuaqingwen Capsules and Lianhuaqingwen Granules were lower than that of other control groups.Conclusion:In the clinical medication process of different diseases，the incidence of adverse reactions of Lianhuaqingwen preparation is significantly lower than that of the control group.